middle.news
How Imagion Biosystems Is Revolutionizing HER2 Breast Cancer Imaging in 2026
3:51pm on Monday 1st of December, 2025 AEDT
•
Healthcare
Read Story
How Imagion Biosystems Is Revolutionizing HER2 Breast Cancer Imaging in 2026
3:51pm on Monday 1st of December, 2025 AEDT
Key Points
IND submission for MagSense® HER2 imaging agent scheduled for December 2025
Phase 2 clinical trial design finalized with Wayne State University collaboration
Reduced imaging agent dose to enhance patient safety and cost efficiency
Optimized MRI sequences developed with Siemens Healthineers support
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imagion Biosystems (ASX:IBX)
OPEN ARTICLE